Avalyn Pharma officer proposes $396K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avalyn Pharma Inc. (AVLN) is named as issuer in officer Melissa Rhodes’s Form 144 notice of intended sale of 13,300 common shares, with an aggregate market value of $395,808 and an approximate sale date of November 17, 2026. The notice says Rhodes acquired the shares that day through exercise of stock options, with cash payment, and lists July 30, 2026, as the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date does Melissa Rhodes’s AVLN notice list?
AI-generated analysis. How Rhea-AI works. Not financial advice.